About lenz therapeutics inc - LENZ
LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.
LENZ At a Glance
LENZ Therapeutics, Inc.
201 Lomas Santa Fe Drive
Solana Beach, California 92075
| Phone | 1-858-925-7000 | Revenue | 19.09M | |
| Industry | Pharmaceuticals: Major | Net Income | -82,127,000.00 | |
| Sector | Health Technology | Employees | 152 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
LENZ Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 24.152 |
| Price to Book Ratio | 1.764 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.865 |
| Enterprise Value to Sales | 8.879 |
| Total Debt to Enterprise Value | 0.005 |
LENZ Efficiency
| Revenue/Employee | 125,578.947 |
| Income Per Employee | -540,309.211 |
| Receivables Turnover | 7.858 |
| Total Asset Turnover | 0.073 |
LENZ Liquidity
| Current Ratio | 14.226 |
| Quick Ratio | 14.088 |
| Cash Ratio | 13.798 |
LENZ Profitability
| Gross Margin | 96.307 |
| Operating Margin | -477.462 |
| Pretax Margin | -427.625 |
| Net Margin | -430.255 |
| Return on Assets | -31.516 |
| Return on Equity | -33.629 |
| Return on Total Capital | -28.801 |
| Return on Invested Capital | -33.55 |
LENZ Capital Structure
| Total Debt to Total Equity | 0.287 |
| Total Debt to Total Capital | 0.286 |
| Total Debt to Total Assets | 0.266 |
| Long-Term Debt to Equity | 0.123 |
| Long-Term Debt to Total Capital | 0.123 |